Aishwarya Gangwar
Research Subjects
Aishwarya Gangwar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akriti Goel
M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, India
1 shared publication - Garima
Chitkara College of Pharmacy, Chitkara University, Punjab, India
1 shared publication - Garima Kapoor
Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
1 shared publication - Hitesh Chopra
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India
1 shared publication - Kuldeep Dhama
Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India
1 shared publication Mamta Naagar
1 shared publication
Latest Publications
- 6 January 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-7
Combinational treatment approaches for acanthosis nigricans: a review
Acanthosis Nigricans is characterised by hyperpigmented, hyperkeratotic, dark, rough patches or plaques distributed in intertriginous areas. Hyperkeratosis is the main concern that leads to the darkening of the skin. Numerous treatment options are available. Topical retinoids are first-line therapy given to treat hyperpigmented plaques where the limiting factor is skin irritation. To combat this, combinational therapies have come into existence and are being used. In this state-of-the-art review, the authors summarize the pathophysiology of AN, provide an update on combinational treatment strategies, and describe the other therapeutic options that have been advantageous so far in the literature for this disease. The paper aims to review the use of retinoids as a first line treatment option as well as combinational approaches to treat acanthosis nigricans skin condition.
- 6 January 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-7
Combinational treatment approaches for acanthosis nigricans: a review
Acanthosis Nigricans is characterised by hyperpigmented, hyperkeratotic, dark, rough patches or plaques distributed in intertriginous areas. Hyperkeratosis is the main concern that leads to the darkening of the skin. Numerous treatment options are available. Topical retinoids are first-line therapy given to treat hyperpigmented plaques where the limiting factor is skin irritation. To combat this, combinational therapies have come into existence and are being used. In this state-of-the-art review, the authors summarize the pathophysiology of AN, provide an update on combinational treatment strategies, and describe the other therapeutic options that have been advantageous so far in the literature for this disease. The paper aims to review the use of retinoids as a first line treatment option as well as combinational approaches to treat acanthosis nigricans skin condition.
- Open Access
- 1 March 2023
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 17 (1) , 89-111
Skin and Soft Tissue Infections: Current Advancement in Epidemiology, Pathogenesis and Management
Skin and soft tissue infections are brought on by invasion of microbes on the skin and underlying soft tissues (SSTIs). They appear in a series of shapes, causes the high level of severeness. Differentiating between SSTI situations that require prompt attention and surgical or medical intervention from those that don’t is difficult. SSTIs are most prevalent in emergency rooms and affect 7% to 10% of hospitalised patients. SSTIs are characterised by inflammatory components as well as other symptoms including fever, quickly growing lesions, and bullae. The creation of a severity categorization approach to specify suitable empirical treatment would improve the management of SSTIs. Based on the patient’s status knowledge of potential infections, an antibiotic medicine is chosen. Oral antibiotics are sufficient for simple mild-to-moderate infections; however, intravenous antibiotics are required for complicated severe infections.
- 1 March 2023
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 17 (1) , 89-111
Open AccessSkin and Soft Tissue Infections: Current Advancement in Epidemiology, Pathogenesis and Management
Skin and soft tissue infections are brought on by invasion of microbes on the skin and underlying soft tissues (SSTIs). They appear in a series of shapes, causes the high level of severeness. Differentiating between SSTI situations that require prompt attention and surgical or medical intervention from those that don’t is difficult. SSTIs are most prevalent in emergency rooms and affect 7% to 10% of hospitalised patients. SSTIs are characterised by inflammatory components as well as other symptoms including fever, quickly growing lesions, and bullae. The creation of a severity categorization approach to specify suitable empirical treatment would improve the management of SSTIs. Based on the patient’s status knowledge of potential infections, an antibiotic medicine is chosen. Oral antibiotics are sufficient for simple mild-to-moderate infections; however, intravenous antibiotics are required for complicated severe infections.
- Open Access
- 20 December 2021
- Published by MDPI AG in Future Pharmacology
- Vol. 1 (1) , 80-103
Recent Advances in Mupirocin Delivery Strategies for the Treatment of Bacterial Skin and Soft Tissue Infection
Skin and soft tissue infections (SSTIs) have increased problematically in hospital and ambulatory settings due to the poor immunity of hosts and multidrug-resistant pathogens. Mupirocin (MUP), a global topical antibiotic, is used for the treatment of SSTIs caused by various pathogens due to its unique mechanism of action. However, the therapeutic efficiency of MUP is hampered due to the protein binding and drug resistance caused by frequent use. A combined report covering the various aspects of MUP, such as the synthesis of the novel formulation, loading of the drug, and application against various skin infections, is missing. This comprehensive review focuses on various novel drug delivery strategies such as composite biomaterials/scaffold, hydrogel dressings, liposomes, liposomal hydrogel, microparticles/microspheres, microsponges, nanocapsules, nanofibers, silicone-based adhesive patches, and topical sprays. The therapeutic effect of the MUP can be synergized by combining with other agents and using novel strategies. The objective is to enhance patient compliance, decrease the resistance, magnify the delivery of MUP, and overcome the limitations of conventional formulations. Moreover, the carriers/dressing materials are biocompatible, biodegradable, stimulate wound healing, protect the wound from external environmental contamination, adsorb the wound exudates, and are permeable to oxygen and moisture. This review will help researchers to explore further the treatment of various bacterial skin infections by using MUP-loaded novel formulations with better efficacy, utilizing the novel nanostructures or combinatorial methods.
- 20 December 2021
- Published by MDPI AG in Future Pharmacology
- Vol. 1 (1) , 80-103
Open AccessRecent Advances in Mupirocin Delivery Strategies for the Treatment of Bacterial Skin and Soft Tissue Infection
Skin and soft tissue infections (SSTIs) have increased problematically in hospital and ambulatory settings due to the poor immunity of hosts and multidrug-resistant pathogens. Mupirocin (MUP), a global topical antibiotic, is used for the treatment of SSTIs caused by various pathogens due to its unique mechanism of action. However, the therapeutic efficiency of MUP is hampered due to the protein binding and drug resistance caused by frequent use. A combined report covering the various aspects of MUP, such as the synthesis of the novel formulation, loading of the drug, and application against various skin infections, is missing. This comprehensive review focuses on various novel drug delivery strategies such as composite biomaterials/scaffold, hydrogel dressings, liposomes, liposomal hydrogel, microparticles/microspheres, microsponges, nanocapsules, nanofibers, silicone-based adhesive patches, and topical sprays. The therapeutic effect of the MUP can be synergized by combining with other agents and using novel strategies. The objective is to enhance patient compliance, decrease the resistance, magnify the delivery of MUP, and overcome the limitations of conventional formulations. Moreover, the carriers/dressing materials are biocompatible, biodegradable, stimulate wound healing, protect the wound from external environmental contamination, adsorb the wound exudates, and are permeable to oxygen and moisture. This review will help researchers to explore further the treatment of various bacterial skin infections by using MUP-loaded novel formulations with better efficacy, utilizing the novel nanostructures or combinatorial methods.